Navigation Links
Blood pressure drugs may lengthen lives of melanoma patients
Date:9/20/2011

COLUMBUS, Ohio Beta-blocker drugs, commonly used to treat high blood pressure, may also play a major role in slowing the progression of certain serious cancers, based on a new study.

A review of thousands of medical records in the Danish Cancer Registry showed that patients with the skin cancer melanoma, and who also were taking a specific beta-blocker, had much lower mortality rates than did patients not taking the drug.

The report, published in the current issue of the journal Cancer Epidemiology, Biomarkers & Prevention, summarized the work of a team of researchers at Ohio State University's Institute for Behavioral Medicine Research (IBMR) and the Comprehensive Cancer Center.

If the results are confirmed in a planned clinical trial, this might be an additional adjunct treatment for cancer patients facing a poor prognosis.

At the center of this research is the fact that certain molecules that play important roles in the immune system also appear to promote both tumor growth and metastasis, the shedding and spreading of tumor tissue to other parts of the body.

"The work started with some earlier studies where we discovered that certain tumor cells had receptors to two specific catecholamine stress hormones epinephrine and norepinephrine," explained Ron Glaser, professor of molecular virology, immunology and medical genetics and director of the IBMR.

"When either of these hormones bind to the tumor cell receptors, it stimulates the production of vascular endothelial growth factor (VEGF), interleukin-8 (IL-8), interleukin-6 (IL-6) and certain matrix metalloproteins all molecules known to stimulate blood flow to tumors, enhancing their growth, and promoting metastasis."

The earlier studies first used tissue from a nasopharyngeal carcinoma cell line, and later from both multiple myeloma and melanoma cell lines. When treated with the beta-blocker propranol, all cells stopped producing the tumor-enhancing molecules. Similar work by other scientists showed similar results with ovarian cancer tissues.

Then the team turned to Stanley Lemeshow, a professor and dean of the College of Public Health at Ohio State. Lemeshow had previously partnered with colleagues in Denmark and knew that country had a vast database of patient information, including records of all Danish cancer patients for decades, as well as pharmacy records of all drugs prescribed for those patients.

"These databases can be linked together and by doing so, you have the ability to find patients with melanoma who had previously been prescribed beta-blockers," Lemeshow said.

The researchers looked at melanoma patients who had taken beta-blockers and at those who hadn't to determine whether the former group exhibited longer survival.

"Among patients diagnosed with melanoma, those who were taking beta-blockers when their cancer was diagnosed experienced longer survival than those patients who weren't taking the drug," Lemeshow said.

"Their chance of surviving for a specified number of years improved by 13 percent."

When the researcher looked at all causes of death among melanoma patients not just melanoma their chances of survival were improved by 19 percent.

"We're talking about survival time, here. They simply lived longer."

Eric Yang, an associate member of the IBMR and assistant research professor of internal medicine, said that epinephrine and norepinephrine may stimulate, or induce, the production of these tumor-promoting molecules.

"The idea is that if you treat a patient with beta-blockers, then you can counteract 'epi' and 'norepi' and lower the amounts of those molecules that induce tumor progression, perhaps halting it," Yang said.

That's the idea behind the clinical trial the researchers hope to begin soon.

"That's what has us so excited," Glaser explained. "This drug is relatively inexpensive. It isn't chemotherapy so you don't lose your hair or get sick. It doesn't kill the cancer cells, but it may slow the disease.

"This would be adjunct therapy that could be provided in addition to the normal chemotherapy patients receive."

"So far, we've found an association between beta-blocker use and survival time for melanoma patients," Lemeshow said. "The clinical trial should give us even stronger evidence."


'/>"/>

Contact: Ronald Glaser
glaser.1@osu.edu
614-292-5526
Ohio State University
Source:Eurekalert

Related medicine news :

1. Inflammatory Bowel Ups Risk for Blood Clots
2. Bowel disease link to blood clots
3. Local Blood Supply Impacted by Wednesdays Severe Snow Storm
4. PERSONALABS Offers Discounted Healthy Heart Online Blood Tests in February
5. China Cord Blood Corporation Warrant Registration Statement Declared Effective by SEC
6. NIH grants to Childrens Hospital will advance novel stem cell treatments for blood disorders
7. Bilberry Seems to Act Against Blood Sugar
8. Johns Hopkins scientists develop personalized blood tests for cancer using whole genome sequencing
9. UCR researcher identifies mechanism malaria parasite uses to spread in red blood cells
10. NHLBI, CDC launch surveillance and research program for inherited blood diseases
11. IOM report declares high blood pressure a neglected disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... On ... as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle ... honor of the city’s history as home to some of the world’s leading providers ...
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of ... their offering. The current ... environment for MedImmune to enter. The US ageing population creates ... drive considerable growth for effective anti-influenza medications. The introduction of ... but development is still in its infancy. ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, ... a Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, ... winners, announced today online at www.diabetesscholars.org by ... 1 diabetes stand in the way of academic and ... the Foundation,s scholarship program since 2012, and continues to ...
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
Breaking Medicine Technology: